ClinicalTrials.Veeva

Menu

Project-0027. Lay User Usage Study

Swiss Precision Diagnostics (SPD) logo

Swiss Precision Diagnostics (SPD)

Status

Completed

Conditions

Pregnancy

Treatments

Other: Professional pregnancy test
Other: Clearblue Marketed Pregnancy test
Other: Clearblue Investigational Pregnancy test

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT02636166
PROTOCOL-0772

Details and patient eligibility

About

Study volunteers will be required to conduct a home pregnancy test (HPT) at the trial centre and provide a sample of urine from the same void for further testing.

Volunteers will then complete a product usage questionnaire and leaflet comprehension questionnaire at site.

Follow-up information will be required from all volunteers as both additional urine sample(s) and pregnancy information to establish true pregnancy status at the study visit.

Full description

Eligible volunteers will be recruited into the study and provide informed consent. Volunteers will then test their urine sample with the investigational HPT according to the device Instructions for use and record their result onto the results sheet. A sample of urine from the same void will be obtained for further testing by the study technicians.

The technician will then test the volunteer's sample with a second investigational HPT, a professional use pregnancy test and a Clearblue Digital HPT, the results of which will be used to provide the volunteer with her pregnancy test result. During technician testing, the volunteer will complete the device usability and leaflet comprehension questionnaires.

At the end of the study visit, all volunteers will be provided with materials to allow follow-up for the determination of pregnancy status.

The majority of volunteers will be requested to provide one additional urine sample, collected 2 days after the study visit. If early pregnancy is suspected the volunteer will be requested to provide an additional 7 daily urine samples following the study visit. All volunteers will be required to provide details of pregnancy status (documented menses or pregnancy confirmation by health care professional) after the study visit.

True pregnancy status will be determined by laboratory tests and clinical information. The study will continue until a minimum of 300 pregnant and 300 not pregnant volunteers have completed the study.

Enrollment

943 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female
  • Aged 18 or over
  • Willing to conduct a personal pregnancy test and reveal their pregnancy status
  • Willing to give informed consent

Exclusion criteria

  • Currently or previously employed by SPD Development Company Ltd. (SPD), Alere, Unipath, Procter and Gamble (P&G), or affiliates.
  • Has an immediate relative* currently or previously employed by SPD, Alere, Unipath or P&G or affiliates
  • Previously used the investigational HPT within the last six months
  • Healthcare professionals (HCP's) with professional experience either using lateral flow based devices or conducting near patient testing
  • Confirmed to be pregnant by a healthcare professional and beyond the first trimester
  • Taken a hormonal preparation containing human chorionic gonadotropin (hCG) in the last month, e.g. Pregnyl®

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

943 participants in 1 patient group

Pregnancy test
Other group
Description:
Clearblue investigational Pregnancy test Clearblue Marketed pregnancy test Professional pregnancy test
Treatment:
Other: Clearblue Investigational Pregnancy test
Other: Professional pregnancy test
Other: Clearblue Marketed Pregnancy test

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems